
|Videos|June 8, 2021
Dr. Tannir on CANTATA study of telaglenastat plus cabozantinib in mRCC
Author(s)Urology Times staff
Nizar M. Tannir, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.
Advertisement
Nizar M. Tannir, MD, MD Anderson Cancer Center, discusses results from the phase 2 CANTATA study of cabozantinib (Cabometyx) plus either the novel glutaminase inhibitor telaglenastat (CB-839) or placebo in patients with advanced/metastatic renal cell carcinoma who progressed on immune checkpoint inhibitors or antiangiogenic therapies.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance
2
Taylor Goodstein, MD, highlights contemporary experience with gene therapies for NMIBC
3
Real-World Evidence in mCSPC Management
4
Jim Hu, MD, discusses new posterior approach to nerve-sparing prostatectomy
5



















